Abstract AU2017200543 The present invention relates to a method of mitigating in a mammal one or more symptoms associated with a disease characterized by amyloid, in particular beta-amyloid, deposits in the brain, or delaying or preventing the onset of said symptoms, said method comprising: administering one or more compounds selected from defined tropinol esters and related quinuclidine esters. Said amyloidogenic diseases include Alzheimer's disease, cognitive impairment, age-related macular degeneration (AMD), cerebrovascular dementia, Parkinson's disease, Huntington's disease, and cerebral amyloid angiopathy. The present invention further relates to a method of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway as characterized by increasing sAPPa and/or the sAPPa/A42 ratio in a mammal, and a method of inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (APP664) in a mammal, via the administration of said defined tropi
